BENDEKA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) — efficacy relative to first-line therapies other than chlorambucil has not been established — or patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
You are about to leave BENDEKAHCP.com and enter a website operated by a third party.
Would you like to continue?
The information on this site is intended
for healthcare professsionals
in the United States. Are you a healthcare
professional in the United States?
For healthcare professionals or patients with specific medical questions about BENDEKA®, please contact Teva Medical Information at:
1-888-4-TEVARX (1-888-483-8279)
